FAB Tag

Fusion Antibodies PLC – FAB – Half-year Report

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its unaudited interim results for the six months ended 30...

Read More

Fusion Antibodies PLC – FAB – Final Results

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, is pleased to announce its final results for the year ended...

Read More

Fusion Antibodies PLC – FAB – Trading update

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on the Company's trading and operations over...

Read More

Fusion Antibodies PLC – Trading update

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on current trading....

Read More

Fusion Antibodies PLC – Half-year Report

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its unaudited interim results for the six months ended 30...

Read More

Fusion Antibodies PLC – Final Results

Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services,announces its final results for the year ended 31 March 2019....

Read More

Fusion Antibodies PLC – Trading Update

Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, provides a business and unaudited trading update for year ended 31 March 2019, confirming the...

Read More

Fusion Antibodies PLC – Trading Statement

Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, provides an update on the Company's trading and progress to date in the current financial year...

Read More

Fusion Antibodies PLC – Half-year Report

Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, announces its unaudited interim results for the six months ended 30 September 2018....

Read More